Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drospirenone and its antialdosterone properties.

A R Genazzani1, P Mannella, T Simoncini

  • 1Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy.

Climacteric : the Journal of the International Menopause Society
|March 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum allopregnanolone in women with postpartum "blues".

Obstetrics and gynecology·2001
Same author

The use of a starting dose of recombinant follicle stimulating hormone for controlled ovarian hyperstimulation: a randomized pilot study.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
Same author

Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
Same author

Ovarian follicular fluid contains immunoreactive estriol: lack of correlation with estradiol concentrations.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
Same author

Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
Same author

Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats.

Neuroendocrinology·2000

Drospirenone offers unique benefits as a progestogen due to its aldosterone receptor antagonism, helping regulate blood pressure and fluid balance. This makes it a potentially superior option for hormone replacement therapy compared to other progestins.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Cardiovascular Science

Background:

  • Drospirenone is a progestogen with a unique pharmacologic profile similar to endogenous progesterone.
  • Unlike other progestins, drospirenone exhibits aldosterone receptor antagonism (PARA).

Purpose of the Study:

  • To elucidate the aldosterone receptor antagonism of drospirenone.
  • To evaluate the potential cardiovascular and blood pressure benefits of drospirenone's antialdosterone properties.

Main Methods:

  • Pharmacological assessment of drospirenone's affinity for the mineralocorticoid receptor.
  • Analysis of drospirenone's effects on the renin-angiotensin-aldosterone system (RAAS).

Main Results:

  • Drospirenone antagonizes aldosterone at the mineralocorticoid receptor, impacting the RAAS.

Related Experiment Videos

  • This antagonism promotes sodium excretion and prevents water retention, offering potential blood pressure benefits.
  • Drospirenone's antialdosterone effects may provide cardiovascular advantages beyond RAAS modulation.

    • Conclusions:

    • Drospirenone's unique aldosterone receptor antagonism distinguishes it from other progestins.
    • Its ability to manage sodium/water balance and cardiovascular parameters makes it an attractive component for hormone replacement therapy.